|
Cong-Mei
Wu, Tian-Hua Huang, Research Center of Reproductive Medicine,
Shantou University Medical College (SUMC), Shantou 515041, Guangdong
Province, China
Xiu-Yi Li, The Ministry of Public Health Radiobiology
Research Unit of Jilin University, Changchun 130021, Jilin Province,
China
Supported by the National Natural Science Fundation of China,
No. 39970229
Correspondence to: Dr. Cong-Mei Wu, Research Center of
Reproductive Medicine, Shantou University Medical College, Shantou
515041, Guangdong Province, China.
cmwu@stu.edu.cn
Telephone: +86-754-8900442
Fax: +86-754-8557562
Received: 2003-12-10
Accepted: 2004-03-02
Abstract
AIM: To construct a pEgr-IFNg
plasmid and to investigate its expression properties of interferon-g
(INF-g)
induced by irradiation and the effect of gene-radiotherapy on the
growth of melanoma.
METHODS: A recombined plasmid, pEgr-IFNg,
was constructed and transfected into B16 cell line with
lipofectamine. The expression properties of pEgr-IFNg
were investigated by ELISA. Then, a B16 melanoma-bearing model was
established in mice, and the plasmid was injected into the tumor
tissue. The tumor received 20 Gy X-ray irradiation 36 h after
injection, and IFN-g
expression was detected from the tumor tissue. A tumor growth curve
at different time points was determined.
RESULTS: The eukaryotic expression vector, pEgr-IFNg,
was successfully constructed and transfected into B16 cells. IFN-g
expression was significantly increased in transfected cells after
X-ray irradiation in comparison with 0 Gy group (77.73-94.60 pg/mL, P<0.05-0.001),
and was significantly higher at 4 h and 6 h than that of control
group after 2 Gy X-ray irradiation (78.90-90.00 pg/mL, P<0.01-0.001).
When the transfected cells were given 2 Gy irradiation 5 times at an
interval of 24 h, IFN-g
expression decreased in a time-dependent manner. From d 3 to d 15
after IFNg
gene-radiotherapy, the tumor growth was significantly slower than
that after irradiation or gene therapy alone.
CONCLUSION: The anti-tumor effect of pEgr-IFNg
gene-radiotherapy is better than that of genetherapy or radiotherapy
alone for melanoma. These results may establish an important
experimental basis for gene-radiotherapy of cancer.
Wu CM, Li XY, Huang
TH. Anti-tumor effect of pEgr-IFNg gene-radiotherapy in B16 melanoma-bearing mice. World
J Gastroenterol 2004;
10(20): 3011-3015
http://www.wjgnet.com/1007-9327/10/3011.asp
INTRODUCTION
Radiotherapy is one of the treatments for cancer. However, its
therapeutic effect is still unsatisfactory, and thus new therapeutic
strategy must be adopted. Gene therapy in combination with
radiotherapy is one of the most important advances[1-4].
The introduction of Egr-1 promoter induced by irradiation has
provided a possible approach to this combination therapy[5-6].
IFNg
is the first cytokine produced by gene engineering and used for
treatment of carcinoma, and has anti-tumor effects. Its antitumor
mechanism includes direct inhibition of tumor cell proliferation,
and indirect action by activating cytotoxic activities[7-18].
In the present study we constructed the pEgr-IFNg
plasmid by connecting IFNg
cDNA to Egr-1 promoter to investigate its expression properties in
B16 cells and its antitumor effect in mice.
MATERIALS
AND METHODS
Construction of pEgr-IFNg
Plasmid
The expression vector for pEgr-IFNg
is shown in Figure 1.
Cell line and transfection
B16 cell line was cultured in MH Radiobiology Research Unit
of Jilin University and maintained in RPMI 1640 (Life Technologies)
with 100 mL/L fetal bovine serum (Hyclone Laboratories),
L-glutamine, 100 mg/mL
of streptomycin, and 100 U/mL of penicillin. The cell line was
incubated at 37 °C in 50 mL/L CO2.
B16 cells were transfected in a 6-well plate when the cells
reached 70% confluence. Solution A was prepared by addition of 10 mg
of pEgr-IFNg
or pcDNA3.1+ to 100 mL
serum-free medium (SFM), and solution B by addition of 10 mL
liposome to 100 mL
SFM. Solutions A and B were mixed at room temperature for 30 min,
then mixed with 0.8 mL SFM, the mixture was added to the rinsed
cells. The medium was replaced with fresh and complete medium 6 h
after transfection.
Protein
determination
Supernatants from different groups were collected for
detection of the IFNg
expression with ELISA kit (Genzyme).
Establishment of B16 melanoma-bearing model
Adult
female Kunming mice were provided by the Experimental Animal Center
of Jilin University, with an average weight of 18±2
g.
A
melanoma-bearing model was established by subcutaneous injection at
right hind limb with 0.1 mL B16 cells ( 5×106
/mL), 10 d later, tumor tissue received multi-focus injection of
plasmids packaged with liposome (20 mg
plasmid and 0.1 mL liposome per mouse) for the experimental groups.
Tumor size was measured. Then, tumor volume (V) was
calculated according to the formula: V (mm3) = L×W2/2,
where, L: the longest diameter of tumor; W: the diameter at right
angles on the largest horizontal section. Tumor growth rate (f) was
the ratio of the volume at different time points over the initial
volume (V0).
Ionizing
irradiation
X-rays of 200 kV and 10 mA with 0.5 mm copper and 1.0 mm
aluminum filter were given at a dose-rate of 0.8639 Gy/min for a
total dose of 2--20 Gy.
Figure 1(PDF)
Construction of plasmid pEgr-IFNg.
B16
cells were seeded in a 6-well plate and randomly divided into
different groups. The experiment groups received X-ray irradiation
of various doses or at different time points, control groups
received sham irradiation simultaneously.
Mice
bearing B16 xenografts (n = 40) were randomly divided into
five groups: control group, 20 Gy group, pcDNA3.1+20 Gy group, pEgr-IFNg
group and pEgr-IFNg+20
Gy group. Thirty-six hours before irradiation, melanoma tissue was
injected with plasmids or buffer at 5 separate sites. Tumor beds
were given 20 Gy X-ray irradiation. Animals of 20 Gy group,
pcDNA3.1+20 Gy group and pEgr-IFNg+20
Gy group were shielded with lead except for the tumor-bearing hind
limb, animals in the other 2 groups were given sham-irradiation at
the same time. Tumors were measured and recorded as previously
described.
RT-PCR
Total RNA were extracted from EC9706 cells and tumor tissue
for RT-PCR. GAPDH was used as an internal reference. Primers were as
follows: GAPDH, forward primer 5’-TGCACCACCAACTGCTTAGC –3’ and
reverse one 5’GGCATGGACTGTGG TCATGAG-3’ mouse IFNg
cDNA, forward primer 5’GATCCTTTGGACCCTCTG ACTT-3’and reverse one
5’AGACAGTGATAAACTATAAATGAGCG-3’
RT-PCR was performed as following: denaturation at 95 °C for 3 min, 30 cycles at 95 °C for 45 s, at 56 °C for 45 s, at 72 °C for 40 s and extension at 72 °C for 10 min.
Statistical
analysis
Student’s t test was used to determine comparability
between groups. P values less than 0.05 were considered
statistically significant.
RESULTS
B16 cell line transfected with pEgr-IFNg
plasmid
Pre- and post-transfection of B16 cells are shown in Figure
2.
IFNg
expressions in B16 cells transfected with pEgr-IFNg
after different doses of X-irradiation
After transfection B16 cells received different doses of
X-ray irradiation. The cells of control group were transfected with
pcDNA3.1+ plasmid. Six hours after irradiation IFNg
expression and mRNA level were detected.
The results showed that IFNg
expression in 2-20 Gy groups was significantly higher than that in 0
Gy group (P<0.05-0.01) (Figure 3).
Figure
2 Pre- and post-transfection
of B16 cells.
A: B:
Figure
3(PDF)
Expression of IFNg
in B16 cells after different doses X-ray irradiation. ( mean±SD,
n = 3) aP<0.05
and bP<0.01
vs 0 Gy group.
After irradiation IFNg
mRNA could be detected in B16 cells(Figure 4). The level of IFNg
mRNA was compared with that of GAPDH, and their ratios are shown in
Table 1. The IFNg
mRNA levels in 2-20 Gy groups were higher than that of 0 Gy group.
Figure 4(PDF)
IFNg
RNA level in B16 cells after different doses of X-ray irradiation.
Lane 1: DL2000 Marker; Lane 2: 0 Gy group; Lane 3: 2 Gy group; Lane
4: 5 Gy group; Lane 5: 10 Gy group; Lane 6: 20 Gy group.
IFNg
expressions in B16 cells transfected with pEgr-IFNg
at different time points after 2Gy irradiation
After transfection B16 cells received 2 Gy of X-ray
irradiation while the control group received sham irradiation. IFNg
protein was detected at different time points after irradiation.
ELISA results showed that the IFNg
expression increased with time from 2 h to 6 h in a time-dependent
manner, and peaked at 6 h, about 1.8 times of that in control group
(P<0.001). However, from 8 h to 48 h post-radiation IFNg
expressions were not significantly different from that in control
group (Figure 5).
Table 1 IFNg
mRNA level in B16 cells after irradiation with different doses
| Dose
(Gy) |
Ratio
of IFNg
mRNA level |
| 0 |
0.819 |
| 2 |
0.972 |
| 5 |
1.347 |
| 10 |
1.950 |
| 20 |
2.144 |
Figure
5(PDF)
Expression time course of IFNg
in B16 cells after 2 Gy X-ray irradiation ( mean±SD,
n = 3) bP<0.01 and dP<0.001
vs control group.
Expression
of IFNg
in B16 cells at different time points after X-ray irradiation
After transfection B16 cells received 2 Gy irradiation while
the control group received sham irradiation. IFNg
expression was detected 6 h later. Irradiation and detection were
repeated 5 times at an interval of 24 h.
The result showed that the IFNg
expression after the first irradiation was the highest, then
decreased in a time-dependent manner. The expressions after the
first 2 times of irradiation were higher than that in control group
(P<0.01-0.001) (Figure 6).
Figure
6(PDF)
Expression of IFNg
in B16 cells at different time points after X-ray irradiation ( mean±SD,
n = 3) bP<0.01
and dP<0.001
vs 0 Gy groups.
Effect
of gene-radiotherapy on tumor growth
Melanoma-bearing mice of different groups were shown in
Figure 7.
Tumor growth rate of pEgr-IFNg
group was significantly slower than that of control group (P<0.001)
between 6 d and 15 d after irradiation (Table 2), so was pEgr-IFNg
plus 20 Gy group compared with control and 20 Gy groups between 3 d
and 15 d after irradiation
(P<0.001).
Table
2 Tumor growth rate
after gene-radiotherapy ( mean±SD, n = 8)
| Group |
f
(V/V0)
on days after irradiation |
| 3
d |
6
d |
9
d |
2
d |
15
d |
| Control |
1.23±0.37 |
3.11±1.5 |
12.29±4.83 |
20.21±7.62 |
22.80±8.50 |
| 20
Gy |
1.57±0.19 |
2.34±0.40 |
3.28±0.68b |
4.18±0.66b |
6.18±1.40b |
| PcDNA3.1+20
Gy |
1.86±0.54 |
1.67±0.40ad |
2.26±0.50bd |
2.86±0.58bd |
5.19±0.66b |
| PEgr-IFNg |
1.38±0.23 |
1.76±0.56b |
2.61±0.75b |
5.23±0.98b |
8.03±2.14b |
| PEgr-IFNg+20
Gy |
0.48±0.10bf |
0.34±0.11bf |
0.38±0.14bf |
0.43±0.11bf |
0.35±0.10bf |
aP<0.05,
bP<0.001
vs control group;
dP<0.01,
fP<0.001
vs 20 Gy group.
Figure
7 Melanoma-bearing mice 15 d
after treatment. A:
B: C:
D:
RT-PCR analysis of IFNg in tumor tissue
Melanoma-bearing mice were injected with plasmids, and the
tumor received 20 Gy X-ray irradiation, 3 d later total RNA from
tumor tissue was extracted for RT-PCR.
GAPDH
bands were shown in all groups, but FNg
cDNA bands were shown only in pEgr-IFNg
and pEgr-IFNg+20
Gy groups (Figure 8).
Figure 8(PDF)
RT-PCR analysis of intratumor IFNg.
Lane 1: DL2000 Marker; Lane 2: control; Lane 3: 20 Gy; Lane 4:
pcDNA3.1+20 Gy; Lane 5: pEgr-IFNg;
Lane 6: pEgr-IFNg+20
Gy.
DISCUSSION
In 1992 Weichselbaum put forward the new therapeutic strategy
that took advantage of the dual tumor-killing effects of genetherapy
and radiotherapy, namely, to choose certain exogenous genes that
could be activated by irradiation and then transcript some cytotoxic
proteins to kill the tumor cells. They also established the
techniques that might be used for target gene therapy of carcinomas[19-25].
It had been reported that Egr-1 was transcriptionally induced
by exposure to irradiation, and its induction by irradiation was
conferred by serum response or CC (A/T) rGG elements in its promoter
region[26-30]. Based on this finding, we firstly
connected IFNg
cDNA with Egr-1 promoter to construct pEgr-IFNg
plasmid to investigate the expression properties in B16 melanoma
cells. Furthermore, a melanoma model was established by subcutaneous
injection of B16 cells, and then plasmids were injected to observe
its antitumor effect in vivo.
Firstly, B16 cells transfected with pEgr-IFNg
received different doses of X-ray irradiation and the IFNg
expression was detected. The results showed that the IFNg
expression level in B16 cells post-transfection induced by
irradiation was higher than that of sham-irradiation group (P<0.05-0.01).
Time-course studies revealed that IFNg
expression reached its peak at 6 h after 2Gy irradiation, and the
maximal level was 1.8 times of that in control group (P<0.01).
Furthermore, after repeated irradiation the IFNg
expression in B16 cells post-transfection reached the peak level
just after the first irradiation, and then decreased in
time-dependent manner. All of these demonstrated that pEgr-IFNg
plasmid could enhance IFNg
expression.
Secondly, the results of in vivo experiments showed that the
proliferation of melanoma was significantly inhibited in pEgr-IFNg
group in comparison with control group between 6 and 15 d after
irradiation (P<0.001). So was pEgr-IFNg
gene-radiotherapy group compared with control and 20 Gy groups
between 3 and 15 d after irradiation (P<0.001). IFNg
expression was detected in melanoma tissue having receivied
injection of pEgr-IFNg
plasmid. These results demonstrated that injection of pEgr-IFNg
improved antitumor effect, and combined pEgr-IFNg
and irradiation showed the most optimal effect.
This
study combined pEgr-IFNg
plasmid and irradiation, and demonstrated much more enhanced
antitumor efficacy than either one in the melanoma model. It was
very easy to administer directly the plasmid into melanoma tissue,
and therapeutic dose could also be administered as required. The
tumor could be effectively exposed to radiation with external beam
or intratumoral sources, or both, to enhance local IFNg
expression and boost local tumor control. Increased IFNg
levels might elicit systemic mediators, such as cytokines and matrix
proteinases, which target occult distant metastases and thereby
further enhance the therapeutic ratio. The absence of systemic
toxicities with intratumoral administration of IFNg
supports the safe addition of pEgr-IFNg
gene radiotherapy to current antitumor protocols.
REFERENCES
1
Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H,
Sukhatme VP, Kufe DW. Gene therapy targeted by
radiation preferentially
radiosensitizes tumor cells. Cancer Res
1994; 54: 4266-4269
2
Liu XF, Zou SQ, Qiu FZ. Construction of HCV-core gene vector
and its expression in cholangiocarcinoma. World J
Gastroenterol
2002; 8: 135-138
3
Gou WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y.
Comparison between chemoembolization combined with
radiotherapy and chemoembolization
alone for large hepatocellular carcinoma. World J Gastroenterol
2003; 9: 1697-1701
4
Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, Hori T,
Hirono S, Hayashi K, Tamaoki T, Tsubouchi H. Gene
therapy targeting for hepatocellular
carcinoma: selective and enhanced suicide gene expression regulated
by a
hypoxia-inducible enhancer linked to
a human alpha-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021
5
Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D,
Weichselbaum RR, Kufe DW. Ionizing radiation activates
transcription of the EGR1 gene via
CArG elements. Proc Natl Acad Sci U S A 1992; 89: 10149-10153
6
Tsai Morris CH, Cao XM, Sukhatme VP. 5' flanking sequence and
genomic structure of Egr-1, a murine mitogen
inducible zinc finger encoding gene.
Nucleic Acids Res 1988; 16: 8835-8846
7
Lokshin A, Mayotte JE, Levitt ML. Mechanism of interferon
beta-induced squamous differentiation and programmed
cell death in human non-small-cell
lung cancer cell lines. J Natl Cancer Inst 1995; 87: 206-212
8
Shiau AL, Lin CY, Tzai TS, Wu CL. Postoperative immuno-gene
therapy of murine bladder tumor by in vivo
administration of retroviruses
expressing mouse interferon-gamma. Cancer Gene Ther 2001; 8: 73-81
9
Siesjo P, Visse E, Sjogren HO. Cure of established,
intracerebral rat gliomas induced by therapeutic immunizations
with tumor cells and purified APC or
adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol
1996; 19: 334-345
10
Saleh M, Jonas NK, Wiegmans A, Stylli SS. The treatment of
established intracranial tumors by in situ retroviral
IFN-gamma transfer. Gene Ther 2000;
7: 1715-1724
11
Li XM, Chopra RK, Chou TY, Schofield BH, Wills Karp M, Huang
SK. Mucosal IFN-gamma gene transfer inhibits
pulmonary allergic responses in mice.
J Immunol 1996; 157: 3216-3219
12
Fujinami K, Ikeda I, Miura T, Kondo I. Combination therapy
with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon
alpha-2B (IFN alpha-2B) for advanced
renal cell carcinoma. Gan To Kagaku Ryoho 1996; 23: 1689-1691
13
Yeow WS, Lawson CM, Beilharz MW. Antiviral activities of
individual murine IFN-alpha subtypes in vivo: intramuscular
injection of IFN expression
constructs reduces cytomegalovirus replication. J Immunol 1998; 160:
2932-2939
14
Ahn EY, Pan G, Vickers SM, McDonald JM. IFN-gammaupregulates
apoptosis-related molecules and enhances
Fas-mediated apoptosis in human
cholangiocarcinoma. Int J Cancer 2002; 1: 445-451
15
Blanck G. Components of the IFN-gamma signaling pathway in
tumorigenesis. Arch Immunol Ther Exp
2002; 50: 151-158
16
Nayak SK, McCallister T, Han LJ, Gangavalli R, Barber J,
Dillman RO. Transduction of human renal carcinoma cells with
human gamma-interferon gene via
retroviral vector. Cancer Gene Ther 1996; 3: 143-150
17
Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, Liu W,
Ellis L, Moscioni AD, Tazelaar J, Fawell S, Qin X, Propert KJ,
Davis A, Fraker DL, Wilson JM, Spitz
FR. Systemic IFN-beta gene therapy results in long-term survival in
mice with
established colorectal liver
metastases. J Clin Invest 2001; 108: 83-95
18
Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott
E, Gilman S, Gladue RP. The anti-tumor activity of anti-CTLA-4
is mediated through its induction of
IFN gamma. Cancer Immunol Immunother 2001; 50: 125-133
19
Weichselbaum RR, Hallahan DE, Sukhatme VP, Kufe DW. Gene
therapy targeted by ionizing radiation. Int J Radiat Oncol
Biol Phys 1992; 24: 565-567
20
Weichselbaum RR, Kufe DW, Advani SJ, Roizman B. Molecular
targeting of gene therapy and radiotherapy. Acta Oncol
2001; 40: 735-738
21
Khodarev NN, Park JO, Yu J, Gupta N, Nodzenski E, Roizman B,
Weichselbaum RR. Dose-dependent and independent
temporal patterns of gene responses
to ionizing radiation in normal and tumor cells and tumor xenografts.
Proc Natl
Acad Sci U S A 2001; 98: 12665-12670
22
Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S,
Weichselbaum RR, Posner MC. Combined gene therapy
and ionizing radiation is a novel
approach to treat human esophageal adenocarcinoma. Ann Surg
Oncol
2002; 9: 500-504
23
Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT,
Salloum RM, Hari D, Dhanabal M, Ramchandran R,
Kalluri R, Sukhatme VP, Kufe DW,
Weichselbaum RR. Antitumor interaction of short- course endostatin
and ionizing
radiation. Cancer J 2000; 6: 287-293
24
Takahashi T, Namiki Y, Ohno T. Induction of the suicide
HSV-TK gene by activation of the Egr-1 promoter with
radioisotopes. Hum Gene Ther 1997; 8:
827-833
25
Griscelli F, Li H, Cheong C, Opolon P, Bennaceur- Griscelli
A,Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P.
Combined effects of radiotherapy and
angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U
S A
2000; 97: 6698-6703
26
Christy B, Nathans D. DNA binding site of the growth factor-
inducible protein Zif268. Proc Natl Acad Sci U S A
1989; 86: 8737-8741
27
Seyfert VL, Sukhatme VP, Monroe JG. Differential expression
of a zinc finger-encoding gene in response to positive
versus negative signaling through
receptor immunoglobulin in murine B lymphocytes. Mol Cell Biol 1989;
9: 2083-2088
28
Joseph LJ, Le-Beau MM, Jamieson GA Jr, Acharya S, Shows TB,
Rowley JD, Sukhatme VP. Molecular cloning,
sequencing, and mapping of EGR2, a
human early growth response gene encoding a protein with
“zinc-binding finger”
structure. Proc Natl Acad Sci U S A
1988; 85: 7164-7168
29
Sukhatme VP. Early transcriptional events in cell growth: the
Egr family. J Am Soc Nephrol 1990; 1: 859-866
30
Cao XM, Koski RA, Gashler A, McKiernan M, Morris, CF, Gaffney
R, Hay RV, Sukhatme VP. Identification and
characterization of the Egr-1gene
product, a DNA-binding zinc finger protein induced by
differentiation and growth
signals. Mol Cell Biol 1990; 10:
1931-1939
Edited
by
Ren
SY and Wang XL Proofread
by Xu FM
| |